Cancer cachexia and cannabinoids.
Anorexia and cachexia are diagnosed in more than two-thirds of all cancer patients with advanced disease, and are independent risk factors for morbidity and mortality. Anorexia, nausea and vomiting often are described as more significant inhibiting factors for quality of life of cancer patients than even intense pain. In 1986, delta-9-tetrahydrocannabinol (THC), the main effective constituent of cannabis, was licensed as an anti-emetic drug in cancer patients receiving chemotherapy. In addition, in clinical studies THC has shown significant stimulation of appetite and increase of body weight in HIV-positive and cancer patients. The appetite-stimulating effect of cannabis itself has also been well documented in many anecdotal cases. There are strong indications that cannabis is better tolerated than THC alone, because cannabis contains several additional cannabinoids, like cannabidiol (CBD), which antagonize the psychotropic actions of THC, but do not inhibit the appetite-stimulating effect. Therefore, we intend to compare the therapeutic effects of whole-plant extracts of cannabis to those of THC (dronabinol) alone in controlled studies.
Gorter
R W
RW
Europäisches Institut für onkologische und immunologische Forschung, Berlin, Germany.
D019167:Appetite Stimulants / Q000627:therapeutic use; D002100:Cachexia / Q000188:drug therapy*; D002186:Cannabinoids / Q000627:therapeutic use*; D013759:Dronabinol / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000503:physiopathology*; D011788:Quality of Life
D019167:Appetite Stimulants; D002186:Cannabinoids; D013759:Dronabinol